Drug Profile
Research programme: biosimilars - Samsung Bioepis/Merck & Co
Alternative Names: Biosimilars - Samsung/BiogenLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Samsung Bioepis
- Class Biological factors; Biological peptides; Biological proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified